SPYGLASS PHARMA, INC.
NASDAQ: SGP (SpyGlass Pharma, Inc.)
Last update: 7 hours ago27.07
-0.58 (-2.10%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | SpyGlass Pharma, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.83 |
|
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nea Management Company, Llc | 30 Jun 2026 | 7,392,301 |
| Sands Capital Alternatives, Llc | 30 Jun 2026 | 2,500,012 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 2,109,953 |
| Vestal Point Capital, Lp | 30 Jun 2026 | 670,000 |
| Deerfield Management Company, L.P. | 30 Jun 2026 | 550,000 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 131,586 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |